Johnson & Johnson JNJ
271.22
0.54
0.20%
as of 25 Sep
- Market cap
- $652.8B
- P/E
- 31.4×
Follow JNJ
S&P 500 Member
Dividend Aristocrat
Cash Flow Champion (3y)
Revenue Champion (3y)
Insider Buys (last 12m)
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Johnson & Johnson (JNJ) Free cash flow
Johnson & Johnson's free cash flow for fiscal 2025 was $20.4B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $22.7B. Over the past ten years it has ranged from $16.8B (fiscal 2016) to $23.2B (fiscal 2019); the current reading is higher than 55% of that period. Johnson & Johnson ranks 1st of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $20.4B | (0.48%) |
| FY2024 | $20.5B | 10.27% |
| FY2023 | $18.6B | 4.95% |
| FY2022 | $17.7B | (13.39%) |
| FY2021 | $20.5B | (0.12%) |
| FY2020 | $20.5B | (11.60%) |
| FY2019 | $23.2B | 6.67% |
| FY2018 | $21.7B | 10.84% |
| FY2017 | $19.6B | 16.66% |
| FY2016 | $16.8B | (14.11%) |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $7.4B | 392.50% |
| Mar 2026 | $1.5B | (74.17%) |
| Dec 2025 | $5.8B | (28.49%) |
| Sep 2025 | $8.1B | 180.06% |
| 42 more quarters | Free account |
Against its own ten years
Low $16.8B
High $23.2B
Ten-year median
$20.4B
Current reading's percentile
55
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| JNJ Johnson & Johnson | $22.7B |
| ABBV AbbVie Inc. compare | $18.2B |
| LLY Eli Lilly and Company compare | $18.2B |
| MRK Merck & Co., Inc. compare | $16.1B |
| NVS Novartis AG compare | $15.2B |
| GILD Gilead Sciences, Inc. compare | $12.9B |
| PFE Pfizer Inc. compare | $11.0B |
| AMGN Amgen Inc. compare | $10.2B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on JNJ
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement